RT Journal Article
SR Electronic
T1 Cadherin 5 expression correlates with poor survival in human gastric cancer
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 217
OP 221
DO 10.1136/jclinpath-2016-203640
VO 70
IS 3
A1 Higuchi, Kyoko
A1 Inokuchi, Mikito
A1 Takagi, Yoko
A1 Ishikawa, Toshiaki
A1 Otsuki, Sho
A1 Uetake, Hiroyuki
A1 Kojima, Kazuyuki
A1 Kawano, Tatsuyuki
YR 2017
UL http://jcp.bmj.com/content/70/3/217.abstract
AB Aims Although expressed in tumour cells of various malignancies, cadherin 5 (CDH5), also known as vascular endothelial cadherin, plays an important role in homotypic cell–cell adhesion among epithelial cells. However, the clinical significance of CDH5 expression in gastric cancer has not been sufficiently demonstrated. In this study, CDH5 expression in gastric cancer was evaluated and the correlations between CDH5 expression and the clinicopathological features and outcomes of the disease were examined.Methods Differentiated-type gastric adenocarcinomas obtained from 102 patients who underwent gastrectomy were analysed. CDH5 expression was assessed by immunohistochemical staining of the membranes of the cancer cells.Results High CDH5 expression was significantly associated with the following clinicopathological variables related to tumour progression: depth of invasion (p=0.012), venous invasion (p=0.013), lymphatic invasion (p=0.001), metastatic lymph nodes (p=0.009), pathological stage (p=0.008) and distant metastasis or recurrent disease (p=0.009). Patients with high CDH5 expression had significantly poorer disease-specific survival (p=0.021), although CDH5 was not determined to be an independent prognostic factor by multivariate analysis.Conclusions CDH5 may play a key role in the progression or metastasis of differentiated-type gastric cancer and serve as a target for its treatment.